Trial Profile

A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LB1410, A Recombinant Anti-PD-1 and Anti-TIM-3 Humanized Bispecific Antibody for Injection in Patients With Advanced Solid Tumors or Lymphoma Keyplus-001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LB 1410 (Primary)
Indications Adenocarcinoma; Anal cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms Keyplus-001
Sponsors L and L Biopharma

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
11 Sep 2025 Planned End Date changed from 11 Mar 2025 to 30 Dec 2028.
11 Sep 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com